PMID- 25932144
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20150501
LR  - 20200930
IS  - 1940-5901 (Print)
IS  - 1940-5901 (Electronic)
IS  - 1940-5901 (Linking)
VI  - 8
IP  - 2
DP  - 2015
TI  - A survey on clinical use of propranolol for infantile hemangiomas in mainland 
      China.
PG  - 2138-46
AB  - OBJECTIVE: To provide a guideline for Chinese clinicians regarding oral 
      propranolol treatment on infantile hemangioma (IH). METHODS: A survey for 
      management of propranolol therapy (clinical consultation, dosage initiation, 
      dosage changing, monitoring of complications and effectiveness evaluation) was 
      performed and was delivered to the Division of Vascular Anomalies (DVA), Chinese 
      Stomatological Association (CSA), and to the Division of Hemangioma and Vascular 
      Malformations (DHVM), Chinese Society of Plastic and Reconstructive Surgery. 
      RESULTS: Data from 31 hospitals were collected and analyzed. In all hospitals, IH 
      patients were treated with oral propranolol as a routine. Twenty-two (71%) of the 
      31 hospitals treated patients with IH as part of a multidisciplinary strategy. 
      Cardiology consultation was routinely sought in 21 (95%) of these 22 hospitals 
      before initiation of propranolol therapy. Sixteen hospitals (52%) recommend an 
      initial propranolol dose of 1 to 1.5 mg/kg/day, in most cases 1.0 mg/kg/day. The 
      dosage frequency of once a day was recommended in 18 (58%) of the surveyed 
      hospitals. The maximum dose of 1.5 mg/kg/day or 2.0 mg/kg/day was suggested in 10 
      (32%) and 13 (42%) hospitals, respectively. Similarly, the optimal dose of 1.5 
      mg/kg/day or 2.0 mg/kg/day was recommended in 11 (37%) and 9 (30%) hospitals, 
      respectively. The duration of therapy varied from 1 to 24 months. Tapering was 
      advised by 10 (40%) hospitals and immediate discontinuation was applied in 13 
      (52%) hospitals. Complications were emphasized by all hospitals. The most common 
      complications were gastrointestinal symptoms (17 of 31 hospitals), whereas the 
      complication most commonly monitored for was changes in heart rate. No rebound 
      effects were reported. CONCLUSIONS: Propranolol has become the first-line agent 
      for IH in mainland China. This is a practical survey which is helpful to 
      standardize and develop a guideline for propranolol therapy.
FAU - Chen, Zheng-Gang
AU  - Chen ZG
AD  - Department of Oral and Maxillofacial Surgery, Ninth People's Hospital, College of 
      Stomatology, Shanghai Jiao Tong University School of Medicine, Shanghai Key 
      Laboratory of Stomatology Shanghai 200011, China ; Department of Oral and 
      Maxillofacial Surgery, Qingdao Municipal Hospital Shandong 266071, China.
FAU - Zheng, Jia-Wei
AU  - Zheng JW
AD  - Department of Oral and Maxillofacial Surgery, Ninth People's Hospital, College of 
      Stomatology, Shanghai Jiao Tong University School of Medicine, Shanghai Key 
      Laboratory of Stomatology Shanghai 200011, China.
FAU - Zhang, Ling
AU  - Zhang L
AD  - Department of Oral and Maxillofacial Surgery, Ninth People's Hospital, College of 
      Stomatology, Shanghai Jiao Tong University School of Medicine, Shanghai Key 
      Laboratory of Stomatology Shanghai 200011, China.
FAU - Zhu, Ling
AU  - Zhu L
AD  - Department of Oral and Maxillofacial Surgery, Ninth People's Hospital, College of 
      Stomatology, Shanghai Jiao Tong University School of Medicine, Shanghai Key 
      Laboratory of Stomatology Shanghai 200011, China.
FAU - Wang, Yan-An
AU  - Wang YA
AD  - Department of Oral and Maxillofacial Surgery, Ninth People's Hospital, College of 
      Stomatology, Shanghai Jiao Tong University School of Medicine, Shanghai Key 
      Laboratory of Stomatology Shanghai 200011, China.
LA  - eng
PT  - Journal Article
DEP - 20150215
PL  - United States
TA  - Int J Clin Exp Med
JT  - International journal of clinical and experimental medicine
JID - 101471010
PMC - PMC4402791
OTO - NOTNLM
OT  - Propranolol
OT  - infantile hemangioma
OT  - medication
OT  - side effects
EDAT- 2015/05/02 06:00
MHDA- 2015/05/02 06:01
PMCR- 2015/02/15
CRDT- 2015/05/02 06:00
PHST- 2014/09/09 00:00 [received]
PHST- 2015/01/17 00:00 [accepted]
PHST- 2015/05/02 06:00 [entrez]
PHST- 2015/05/02 06:00 [pubmed]
PHST- 2015/05/02 06:01 [medline]
PHST- 2015/02/15 00:00 [pmc-release]
PST - epublish
SO  - Int J Clin Exp Med. 2015 Feb 15;8(2):2138-46. eCollection 2015.